Rafael Muniz: Influence Statistics

Rafael Muniz

Rafael Muniz

Academic Behavioral Center, New York, NY; Bayou City Research, Houston, TX; Novartis Pharmaceuticals Corp, East Hanover; and Shionogi, Inc, Florham Park, NJ. | From the ...

Rafael Muniz: Expert Impact

Concepts for which Rafael Muniz has direct influence: Ritalin concerta , Hyperactivity disorder , Laboratory classroom setting , Concerta ritalin , Crossover study , Child cross , Disorder hyperactivity .

Rafael Muniz: KOL impact

Concepts related to the work of other authors for which for which Rafael Muniz has influence: Hyperactivity disorder , Attention deficit , Adults adhd , Lisdexamfetamine dimesylate , Methylphenidate mph , Children adolescents , Nervous stimulants .

KOL Resume for Rafael Muniz

Year
2013

Academic Behavioral Center, New York, NY; Bayou City Research, Houston, TX; Novartis Pharmaceuticals Corp, East Hanover; and Shionogi, Inc, Florham Park, NJ.

2012

From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston; †Westex Clinical Investigations, Lubbock, TX; ‡US Medical, Novartis Pharmaceuticals Corporation, East Hanover, NJ; §Pediatric Trials Division, Clinical Study Centers, LLC, Little Rock, AR; ∥Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, NV; ¶Biostatistics, US Medical; and #Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ.

2010

US Clinical Developmental & Medical Affairs, Neuroscience, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

2009

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

2008

Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

2006

Norvartis Pharmaceuticals, East Hanover, New Jersey.

Dr. Greenhill is with the Research Unit of Pediatric Psychopharmacology at the New York State Psychiatric Institute, New York; Dr. Muniz is with USCD and MA; Ms. Pestreich and Dr. Jiang are with Novartis Pharmaceuticals Corporation, East Hanover, NJ; Dr. Ball is with the CNS Research Institute, Philadelphia; Dr. Levine is with the University of Colorado Health Sciences Center and the Alpine Clinical Research Center, Boulder.

2005

Novartis Pharmaceutical, East Hanover, New Jersey

2004

Novartis Pharmaceuticals Corporation, Children's Developmental Center, Maitland, Florida. *

Prominent publications by Rafael Muniz

KOL-Index: 72724 . ObjectivesThe primary objective was to compare the differences in clinical efficacy of the starting dose of Ritalin® LA™ (20mg) to the starting dose of Concerta® (18mg), in a laboratory school setting for the duration of an entire school day. Secondary objectives were to compare Ritalin® LA™ 20mg with Concerta® 36mg, and Ritalin® LA™ and both Concerta® doses versus placebo across the ...
Known for Ritalin Concerta | School Day | Attention Deficit | Comparative Efficacy
KOL-Index: 14104 . Objective: To compare the rate and extent of absorption of DL-threo-methylphenidate (MPH) from two modified-release MPH formulations at their respective recommended starting doses in healthy adult volunteers.Design: Open-label, randomised, crossover, bioavailability study.Participants: Twenty healthy adult male and female volunteers.Methods: Subjects received single doses of two ...
Known for Oral Administration | Release Formulations | Healthy Adults | Ritalin Concerta
KOL-Index: 11194 . OBJECTIVE: This study compared the efficacy and safety of extended-release dexmethylphenidate (d-MPH-ER) 20 mg/day and 30 mg/day with extended-release racemic methylphenidate hydrochloride (d,l-MPH-ER) 36 mg/day and 54 mg/day, and placebo in children with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting. METHODS: This multicenter, double-blind, crossover ...
Known for Hyperactivity Disorder | Placebo Children | Classroom Study | Release Dexmethylphenidate
KOL-Index: 10241 . Background: Long-acting methylphenidate formulations provide control of attention-deficit hyperactivity disorder (ADHD) symptoms for up to 12 hours; however, not all formulations have rapid onset of therapeutic effect, which is essential for providing symptom control during morning hours. The primary objective of this randomized, double-blind, crossover study was to assess the efficacy of ...
Known for Hyperactivity Disorder | Crossover Study | Daily Dexmethylphenidate | Post Dose
KOL-Index: 9720 . OBJECTIVE: The aim of this study was to assess changes in symptomatology of attention-deficit/ hyperactivity disorder (ADHD) with extended-release dexmethylphenidate (d-MPHER) versus placebo in a laboratory classroom setting. METHODS: This double-blind, placebo-controlled, crossover study randomized 54 children 6-12 years of age, stabilized on methylphenidate 20-40 mg/day. Patients ...
Known for Hyperactivity Disorder | Children Adhd | Child Cross | 20 Day Placebo
KOL-Index: 9697 . BACKGROUND: This multicenter, randomized, fixed-dose, double-blind, placebo-controlled study evaluated efficacy of extended-release dexmethylphenidate (d-MPH-ER) in adults with attention-deficit/hyperactivity disorder (ADHD). METHODS: Randomized adults with ADHD (n=221) received once-daily d-MPH-ER 20 mg, 30 mg, or 40 mg or placebo for 5 weeks. The primary efficacy variable was change from ...
Known for Hyperactivity Disorder | Adults Adhd | Dexmethylphenidate Extended | Illness Surveys
KOL-Index: 9686 . OBJECTIVE: The aim of this study was to compare efficacy and safety of two long-acting formulations of methylphenidate (MPH) for attention-deficit/hyperactivity disorder (ADHD) in school-age children. METHODS: Children 6-12 years of age diagnosed with ADHD and stabilized on MPH (20-40 mg/day) participated in a five-way, randomized, placebo-controlled, single-blind, crossover study ...
Known for Laboratory Classroom Setting | Hyperactivity Disorder | Methylphenidate Formulations | Efficacy Safety
KOL-Index: 8483 . OBJECTIVE: This study compared once-daily dexmethylphenidate extended release (D-MPH-ER) 20 mg/day and placebo over 12 hours in children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting. METHOD: All of the children were stabilized for > or =2 weeks on a total dose (nearest equivalent) MPH 40 mg/day or immediate-release D-MPH 20 mg/day ...
Known for Hyperactivity Disorder | 12 Hours | Children Attention | Child Cross
KOL-Index: 7886 . OBJECTIVE: The efficacy and safety of dexmethylphenidate extended release (d-MPH-ER) was compared to placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD). METHOD: This multicenter, randomized, double-blind, placebo-controlled, parallel-group, two-phase study included 97 patients (ages 6-17 years) with DSM-IV-defined ADHD. The study was carried out between 2001 ...
Known for Hyperactivity Disorder | Adhd Children | Efficacy Safety | Dexmethylphenidate Extended
KOL-Index: 7256 . The objective of this study was to evaluate the safety and efficacy of dexmethylphenidate extended-release (d-MPH-ER) 30 versus 20 mg in children with attention-deficit/hyperactivity disorder (ADHD) in a 12-hour laboratory classroom setting. In a randomized, double-blind, 3-period × 3-treatment, crossover study, children aged 6 to 12 years with Diagnostic and Statistical Manual of Mental ...
Known for Hyperactivity Disorder | 30 Mph | Versus 20 | Attention Deficit
KOL-Index: 6929 . dl-Methylphenidate (MPH) has been widely used to treat attention-deficit/hyperactivity disorder (ADHD) for the last half century. It had been exclusively available in the racemic form, i.e., a 50:50 mixture of d- and l-isomers. However, a single enantiomer formulation, d-MPH (dexmethylphenidate), became available for general clinical use in 2002. For this reason, the intrinsic ...
Known for Lmph Mph | Serotonin 5 | Transport Proteins | Plasma Membrane
KOL-Index: 6880 . OBJECTIVE: This study evaluates dexmethylphenidate extended release (d-MPH-ER) in adults with ADHD. METHOD: Following a 5-week, randomized, controlled, fixed-dose study of d-MPH-ER 20 to 40 mg/d, 170 adults entered a 6-month open-label extension (OLE) to assess long-term safety, with flexible dosing of 20 to 40 mg/d. Exploratory effectiveness outcomes included change from Week 5 on ADHD ...
Known for Adult Adhd | Dexmethylphenidate Extended | Mph 20 | Longterm Safety
KOL-Index: 5654 . Methylphenidate (MPH, Ritalin), has been prescribed to treat attention deficit/hyperactivity disorder (ADHD) since its approval by the FDA over 50 years ago. Diagnoses of pediatric patients with ADHD and the administration of MPH to treat the symptoms have increased in prevalence in recent years. A 2005 study by El-Zein et al. reported statistically significant increases in cytogenetic ...
Known for Hyperactivity Disorder | Attention Deficit | Behavior Therapy | Peripheral Blood
KOL-Index: 5037 . OBJECTIVE: This 5-week, multicenter, double-blind, placebo-controlled, parallel-group investigation is the first fixed-dose study to evaluate efficacy and tolerability of three doses of (10, 20, or 30 mg, once daily [o.d.]) dexmethylphenidate hydrochloride (HCl) extended-release (d-MPH XR; Focalin XR) across multiple settings to treat pediatric attention-deficit/hyperactivity disorder ...
Known for Dexmethylphenidate Extended | Hyperactivity Disorder | Attention Deficit | Adhd Symptoms

Key People For Ritalin Concerta

Top KOLs in the world
#1
James M Swanson
hyperactivity disorder children adhd attention deficit
#2
Timothy Edwin Wilens
bipolar disorder attention deficit adults adhd
#3
Laurence Lee Greenhill
hyperactivity disorder suicidal behavior children adhd
#4
Oscar Gary Bukstein
practice parameter substance abuse hyperactivity disorder
#5
Sharon B Wigal
hyperactivity disorder children adhd attention deficit
#6
Suneel K Gupta
nicotine transdermal consultancy funding fentanyl hcl
Similar searches    ritalin concerta

Academic Behavioral Center, New York, NY; Bayou City Research, Houston, TX; Novartis Pharmaceuticals Corp, East Hanover; and Shionogi, Inc, Florham Park, NJ. | From the *Menninger Department of Psychiatry, Baylor College of Medicine,Houston;